Recombinant antibody composition
View Patent ↗The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
1. A recombinant version of an antibody capable of specifically binding an antigen, said recombinant version comprising the light chain of the antibody and a recombinant heavy chain comprising the heavy chain variable domain of the antibody and a heterologous heavy chain constant domain comprising the amino acid sequence of SEQ ID NO:50, wherein said recombinant version retains the binding specificity of said antibody.
2. The recombinant antibody according to claim 1 , which specifically binds to protein A.
3. The recombinant antibody according to claim 1 , wherein said recombinant antibody has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains bound to the Fc region of the antibody are sugar chains in which fucose is not bound to N-acetylglucosamine in the reducing terminal in the sugar chains.
4. A composition comprising the recombinant antibody of claim 1 .
5. The composition according to claim 4 , wherein said recombinant antibody has complex type N-glycoside-linked sugar chains in the Fc region, wherein the ratio of sugar chains in which fucose is not bound to N-acetylglucosamine in the reducing terminal of the sugar chains among the total complex type N-glycoside-linked sugar chains which bind to the Fc region contained in the composition is 20% or more.